Is Alumis Inc. (ALMS) a Buy, Sell, or Hold?
Alumis Inc.
NASDAQ:ALMS
$28.565 USD
$1.28 (4.71%)
- Volume
- 896.47K
- Average Volume
- 1.35M
- Market Capitalization
- $3.53B
- P/E Ratio
- -14.96
- Dividend Yield
- 0.00%
- Price Target
- $39.00
- Year High
- $31.35
- Year Low
- $3.25
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.51
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Martin Babler |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ALMS |
| CUSIP | 022307102 |
| CIK | 0001847367 |
| Web | https://www.alumis.com |
| Phone | (650) 231-6625 |
| Currency | USD |
| Employees | 223 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.06 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.51 |
| Quick Ratio | 7.51 |
| Cash Ratio | 0.90 |
Sales & Book Value
| Annual Sales | $24.05M |
| Price / Sales | 419.64 |
| Cash Flow | -3.02 |
| Price / Cash Flow | -9.35 |
| Price / Book | 6.30 |
Price Target and Rating
| Average Stock Price Forecast | $39.00 |
| High Stock Price Forecast | $51.00 |
| Low Stock Price Forecast | $25.00 |
| Forecast Upside/Downside | -26.76% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.32 |
| Trailing P/E Ratio | -14.96 |
| PEG Ratio | -0.10 |
| P/E Growth | -0.10 |
| Net Income | $-243.32M |
| Net Margin | -2825.70% |
| Pretax Margin | -2927.59% |
| Return on Equity | -54.63% |
| Return on Assets | -35.35% |
Financials Score
| AltmanZ Score | 16.61 |
| Piotroski Score | 1.00 |
| Working Capital | 461.5M |
| Total Assets | 671.59M |
| Ebit | -417.58M |
| Market Cap | 3.47B |
| Total Liabilities | 104.57M |
Poll Results
About Alumis Inc. (NASDAQ:ALMS) Stock
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquar ... tered in South San Francisco, California.
Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon
2026-06-25 17:58:44
Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeucitinib in psoriasis and SLE. Phase 3 data for envudeucitinib showed strong efficacy and safety, though not outright superiority versus competitors, and twice-daily dosing is a minor drawback. Upcoming 2026 catalysts include long-term psoriasis data, NDA submission, and pivotal SLE data, all critical for valuation and acquisition potential.
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
2026-05-24 10:13:59
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
2026-05-17 14:13:40
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
2026-05-15 18:36:41
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
2026-05-14 16:05:00
– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
2026-05-10 05:33:01
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Frequently Asked Questions
-
What is the current Alumis Inc. (ALMS) stock price?
-
Alumis Inc.(NASDAQ:ALMS) stock price is $28.565 in the last trading session. During the trading session, ALMS stock reached the peak price of $31.35 while $3.245 was the lowest point it dropped to. The percentage change in ALMS stock occurred in the recent session was 4.71% while the dollar amount for the price change in ALMS stock was $1.28.
-
ALMS's industry and sector of operation?
-
The NASDAQ listed ALMS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALMS?
-
John R. Schroer | Chief Financial Officer
Mark Bradley | Chief Development Officer
Grace Halteh | Senior Vice President & Head of Quality and Regulatory
Sanam Pangali | Chief Legal Officer & Corporate Secretary
Jorn Drappa | Chief Medical Officer & Head of Research and Development -
How many employees does ALMS have?
-
Number of ALMS employees currently stands at 223. ALMS operates from 280 East Grand Avenue, South San Francisco, CA 94080, US.
-
Link for ALMS official website?
-
Official Website of ALMS is: https://www.alumis.com
-
How do I contact ALMS?
-
ALMS could be contacted at phone #(650) 231-6625 and can also be accessed through its website. ALMS operates from 280 East Grand Avenue, South San Francisco, CA 94080, US.
-
How many shares of ALMS are traded daily?
-
The average number of ALMS shares traded daily for last 3 months was 1.35M.
-
What is the market cap of ALMS currently?
-
The market value of ALMS currently stands at $3.53B with its latest stock price at $28.565